Eine Labormitarbeiterin bei einer mikroskopischen Untersuchung. (Symbolbild)
Dienstag, 16.10.2012 14:35 von | Aufrufe: 173

BG Medical Technologies Completes Process to Upgrade OTC Markets Listing

Eine Labormitarbeiterin bei einer mikroskopischen Untersuchung. (Symbolbild) © Likoper / iStock / Getty Images Plus / Getty Images http://www.gettyimages.de/

PR Newswire

LOS ANGELES, Oct. 16, 2012 /PRNewswire/ -- BG Medical Technologies, Inc. (OTC: RIGH) is pleased to announce that it has submitted all necessary filings and the accompanying attorney opinion letter required to fully restore the Company to "Current Information" on OTC Markets. The new status is expected to be displayed within several days.

Q1 and Q2 financials have been resubmitted to reflect an increased level of disclosure congruent with OTC Market Group's Guidelines for Providing Adequate Current Information. The Company has also obtained new accounting and legal firms, replacing those associated with previous management and past filings for the public entity.

"This forward momentum represents our ongoing commitment to completing the steps associated with the reverse merger from earlier this year," stated CEO Angel Stanz. "Our upgraded team is strongly committed to regulatory compliance and will be assisting us through the planned audit process and additional filings."

About BG Medical Technologies
BG Medical Technologies develops technology and research software for the health industry with a focus on patient solutions for natural and herbal treatments, including medical cannabis. The Company collects data through a network of proprietary software, utilized by patients, retail operators, and medical professionals. The Company's current flagship product, BudGenius.com, is a social web platform designed to assist cannabis patients in selecting regionally available medicine that is paired to their needs. The Company operates an analytical chemistry laboratory designed for natural medicine study, utilized to determine potency and safety guidance for patients and medicine manufacturers.

For more information please visit:
http://www.BgMedTech.com 
http://www.BudGenius.com  

BG Medical and its companies do not sell, grow, harvest, cultivate, nor distribute medical cannabis.

The foregoing press announcement contains forward-looking statements that can be identified by such terminology such as "believes," "expects," "potential," "plans," "suggests," "may," "should," "could," "intends," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations could be affected by, among other things, uncertainties relating to our success in completing acquisitions, financing our operations, entering into strategic partnerships, engaging management and other matters disclosed by us in our public filings from time to time. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.


ARIVA.DE Börsen-Geflüster

Kurse

-   $
0,00%
Rightsmile Chart

Contact:
Angel Stanz
Chief Executive Officer
pr(at)bgmedtech(dot)com
(855) 723-3283

SOURCE BG Medical Technologies, Inc.

Werbung

Mehr Nachrichten zur Rightsmile Aktie kostenlos abonnieren

E-Mail-Adresse
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.